Health Literacy

Abbreviation
HLT
Description
A set of three health literacy screening questions for detecting patients with inadequate or marginal health literacy
Category
Health Cognitions & QOL
Physical/General Health
Division
HEAL Study
Investigator(s)
Title
Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder
Short Description
The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.
Release Date
Jul 19, 2024
Description
This is a 19-week, multi-center, parallel group study that includes: 1) up to 3 weeks for screening; 2) a 13-week Treatment Phase consisting of a 1-week, single-blind run-in period, when all subjects receive twice daily 15 mg acetazolamide capsules (a medication adherence marker), followed by randomization to either twice daily 10 mg lorcaserin or placebo capsules for the remaining 12 weeks; and 3) a 3-week follow-up period, with scheduled visits during Study Weeks 14 and 16.
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links

Drug and Drug Problems Perceptions Questionnaire

Abbreviation
DDPPQ
Description
The 22-item DDPPQ was developed to measure mental health professionals' attitudes to working with drug users. One of its possible uses is to help ascertain the training requirements of staff who work with drug users. It may also be used to evaluate the impact of education programs on staff's attitudes. The 22-items in the DDPPQ include statements such as "I feel I have a working knowledge of drugs and drug related problems," "I feel I know how to counsel drug users over the long term," "I feel I have the right to ask patients/clients questions about their drug use when necessary," and "I feel there is little I can do to help drug users." Respondents rate each statement on a 7-point Likert scale with 1 corresponding to "strongly agree" and 7 to "strongly disagree."
Category
Mental Health
Substance Use
Impulsivity and General Trait & Behavior Scales
Clinical Measures
Subcategory
Diagnostic
Drugs

Difference and Disdain

Abbreviation
DaD
Description
The Difference and Disdain scale (DaD) is a 9-item measure that assesses how individuals view others in stigmatized groups compared to the general population. Responses are rated on a scale from 1 to 9, where 1 represents a belief that stigmatized people are similar to/favorable compared to others in the general population and 9 represents a belief that they are different from/unfavorable compared to the general population. This measure has been adapted to ask about people with substance use problems and then criminal involvement (18 items total). Each scale ranges from 9–81 with higher scores indicating more differences/disdain.
Category
Substance Use
Impulsivity and General Trait & Behavior Scales
Clinical Measures
Subcategory
Diagnostic
Division
HEAL Study
Title
Reducing Stigma toward People with Opioid Use Disorder among Primary Care Clinicians
Short Description
This project will evaluate an intervention to reduce stigma in PCCs by integrating stigma reduction training into the Opioid Wizard training.
Release Date
May 24, 2024
Description
This study will use a randomized controlled trial design, in which PCCs will be randomized to receive one of two trainings delivered via MyLearning: a stigma reduction training or an attention control training. Outcome assessments will occur immediately following the training delivery (PCC initial survey), at 3 months following training completion (PCC follow-up survey), and in the 6 months following the training (objective indicators of PCC Opioid Wizard use, waivered clinician prescribing behavior, and waiver status).
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Division
HEAL Study
Investigator(s)
Title
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study (CHOICES)
Short Description
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol use disorders.
Release Date
Mar 07, 2024
Description
This is an open-label, randomized, pilot trial of XR-NTX vs. treatment as usual (TAU) for treatment of opioid and alcohol use disorders in HIV-infected patients, whose goal is to determine the acceptability and feasibility of XR-NTX in HIV practice and inform development of a multi-site comparative effectiveness trial of XR-NTX vs. TAU in HIV clinics. During the study start-up period, we will conduct a survey of HIV provider attitudes toward opioid antagonist therapy at 15 high-volume HIV clinics to assess willingness to prescribe antagonist therapy and inform the site selection process (Aim 1). During pilot study implementation, we will survey HIV-infected patients regarding attitudes toward opioid antagonist therapy (Aim 2), track rate of participant recruitment (Aim 3), and randomize those who have untreated opioid and/or alcohol use disorders to receive XR-NTX vs. TAU (Aim 4). Participants will attend study visits every 4 weeks for 16 weeks. Treatment initiation will be assessed at 4 weeks and retention at 16 weeks (4 XR-NTX injections). Randomization will continue until a maximum of 50 participants or 12 months are reached. Pilot study duration will be a maximum of 17 months (maximum 12 months recruitment + 5 months study participation for those enrolled at the end of the recruitment period). We will assess feasibility of a multi-site trial of XR-NTX vs. TAU by addressing four pilot study specific aims.
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Division
HEAL Study
Investigator(s)
Title
Treatment-as-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with NIDA CTN-0051
Short Description
CTN-0051-A2 (also referred to as “ancillary study”) is an observational study intended to describe opioid use amongst opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs affiliated with CTN-0051 (referred to as “parent study”).
Release Date
Feb 15, 2024
Description
The primary objective is to follow a group of participants with opioid use disorder to estimate treatment-as-usual rates of opioid use clinical outcomes following discharge to the community from detoxification and/or short-term residential programs. This is an observational study of participants with opioid use disorder leaving the same detoxification and/or short-term residential units from which participants for CTN-0051 are recruited, but who are discharged to TAU in the community. We will collect similar drug use measures as are collected in CTN-0051 that will allow us to estimate (1) days to first use and days to regular use, (2) number of days of use during the first four and eight weeks post-discharge to the community, and (3) number of positive, negative and missing UDSs at weeks 1, 4 and 8 post-discharge to the community.
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Division
HEAL Study
Investigator(s)
Title
Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
Short Description
The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.
Release Date
Jul 26, 2023
Description

The CTN-0055 CHOICES pilot study demonstrated the feasibility of extended-release naltrexone (XR-NTX) for treatment of opioid use disorder in HIV primary care. The CTN-0067 CHOICES scale-up study builds on lessons learned from the pilot and uses the Consolidated Framework for Implementation Research to advance understanding of XR-NTX adoption in HIV primary care clinics. The study is an open-label, randomized, comparative effectiveness trial of office-based XR-NTX for 24 weeks (6 monthly injections) versus treatment as usual (TAU) in HIV-infected participants with untreated opioid use disorder. Each participant will be engaged in the overall study for 25 to 28 weeks, depending on the speed of screening and enrollment procedures.

Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links
Division
HEAL Study
Title
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Short Description
The goal of the study is to validate a Prescription Drug Monitoring Program-based opioid risk metric to discriminate between low, moderate, and high-risk opioid use disorder. The World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO ASSIST) will be used as the gold standard instrument that defines patient risk levels. No intervention or hypothesis will be tested.
Release Date
Apr 13, 2023
Description

This study will evaluate the concurrent validity of a PDMP-based opioid risk metric as a clinical measure of high risk opioid use and establish clinically useful risk-level thresholds relative to the widely validated gold standard of the World Health Organization Alcohol, Smoking, and Substance Involvement Screening Test (WHO ASSIST). This study is a one group, cross-sectional, health assessment study. Participants who enroll in the study will complete on-line surveys at a single time point. Approximately 1,523 patients will be recruited from approximately 15 community community pharmacies. Trained pharmacy staff will inform potentially eligible participants, or individuals receiving at least one prescription(s) for potentially eligible participants, of the survey opportunity. Patients recruited will complete validated measures to assess opioid use and risk behaviors, substance use, and physical and mental health. A series of a priori analyses will be conducted to evaluate the validity of the PDMP-based opioid risk metric relative to the widely validated gold standard WHO ASSIST and to identify cutoff thresholds. Correlational, regression, and Cohen's Kappa statistical analyses will also be conducted to evaluate the relationship between the risk metric and the WHO ASSIST.

Keywords
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Links